MacroGenics’ IND for colorectal cancer drug candidate MGD007 gets FDA clearance
MGD007 is a Dual-Affinity Re-Targeting (DART) protein in development to treat colorectal cancer. The company will receive a $5m milestone payment from Servier, France’s largest privately-held pharmaceutical company,